Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ASSESSMENT OF CUMULATIVE RISK OF CARDIO-VASCULAR DISEASES

https://doi.org/10.20996/1819-6446-2005-1-3-54-56

Full Text:

Abstract

Assessment of cumulative risk of cardio-vascular diseases.

About the Authors

S. A. Shalnova

Russian Federation


O. V. Vikhireve

Russian Federation


References

1. Флетчер Р., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. Пер. с англ. М. Медиа Сфера 1998, 345 С.

2. Бритов А.Н. Вторичная профилактика артериальной гипертонии в организованных популяциях: Автореф. дисс. ... докт. мед. наук. М. 1985, 36 с.

3. Чазова Л.В. Многофакторная профилактика ИБС среди населения. Автореф. дисс. ... докт. мед. наук. М. 1984, 38 с.

4. Puska P, Nissinen A, Tuomilehto J et al. The community based strategy to prevent coronary heart disease: conclusions from the ten years of the North Karelia Project. Ann Rev Pub Health 1985;6:147-93.

5. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996;275:1571-6.

6. Puska P, Vartiainen E, Tuomilehto J, Salomaa V, Nissinen A. Changes in premature deaths in Finland: successful long-term prevention of cardiovascular diseases. Bull World Health Organ 1998;76(4):419-25.

7. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coro￾nary risk profile. A statement for health professionals. Circulation 1991;83:356-62.

8. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.

9. Menotti A, Puddu PE, and Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000;21:365-70.

10. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovas J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Comm Health 2003;57:634-8.

11. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;3:1-9.

12. Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002;31:817-22.

13. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267-70.

14. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, et al. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? Eur Heart J 2003;24:1903-11.

15. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.

16. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(Suppl 1):S1-78.

17. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, et al. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ 2005;331;1551-4.

18. Health Organization. Core health indicators. Norway. www.who.int/country/nor/en.

19. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.

20. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.

21. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004;364:849-57.

22. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001;323:75-81.

23. Clayton TC, Lubsen J, Pocock SJ, Voko Z, Kirwan BA, Fox KA, Poole-Wilson PA. Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large ran￾domised trial cohort of patients. BMJ 2005;331(7521):869-73.

24. Daly C, Norrie J, Murdoch DL, Ford I, Dargie HJ, Fox K. The value of routine non-invasive tests to predict clinical outcome in stable angina. Eur Heart J 2003;24:532-40.

25. O'Toole L, Grech ED. Chronic stable angina: treatment options. BMJ 2003;326:1185-8.


For citation:


Shalnova S.A., Vikhireve O.V. ASSESSMENT OF CUMULATIVE RISK OF CARDIO-VASCULAR DISEASES. Rational Pharmacotherapy in Cardiology. 2005;1(3):54-56. (In Russ.) https://doi.org/10.20996/1819-6446-2005-1-3-54-56

Views: 436


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)